Advertisements



Sarepta Soars As Pfizer"s DMD Prospects Languish

Sarepta Soars As Pfizer"s DMD Prospects Languish.....»»

Category: topSource: seekingalphaJul 11th, 2019

Bulls And Bears Of The Week: Boeing, GM, Pfizer, Starbucks And More

Benzinga has examined the prospects for many investor favorite stocks over the past week. Bullish calls included an underappreciated automaker and a leading pharmaceutical. Bearish calls included FAANG stocks and an aerospace giant. read more.....»»

Category: blogSource: benzingaAug 3rd, 2019

Mylan"s stock soars after merger deal with Pfizer"s Upjohn

Shares of Mylan N.V. soared 24% in premarket trading Monday, after the generic drug maker confirmed it was merging .....»»

Category: topSource: marketwatchJul 29th, 2019

Mylan"s stock soars 25% premarket after report of talks to merge off-patent drug business with Pfizer, Q2 results

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchJul 29th, 2019

Sarepta Gains After Pfizer Suffers A Setback With Gene Therapy For DMD

Sarepta Gains After Pfizer Suffers A Setback With Gene Therapy For DMD.....»»

Category: topSource: seekingalphaJul 9th, 2019

Pfizer’s Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD King

Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did not necessarily live up to expectations, there is a winner in this......»»

Category: blogSource: 247wallstJun 29th, 2019

"Almost impossible" for Pfizer to compete with Sarepta, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 28th, 2019

Sarepta surges after Pfizer gene therapy data raises safety concerns

Shares of Sarepta Therapeutics Inc surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc ......»»

Category: topSource: reutersJun 28th, 2019

Sarepta has clear lead in DMD after Pfizer disappoints, says William Blair

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 28th, 2019

Sarepta "still in pole position" in DMD after Pfizer data, says JPMorgan

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 28th, 2019

Sarepta jumps, Solid slides after Pfizer DMD gene therapy trial paused

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 28th, 2019

Sarepta, Solid jump at start of Pfizer presentation on mini-dystrophin data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 28th, 2019

Bitcoin soars past $13,000 as Facebook"s Libra fuels demand

Bitcoin jumped to an 18-month high on Wednesday, as investors looked for safety in alternative investments amid geopolitical tension, and cheered prospects that Facebook Inc's Libra token could push cryptocurrencies into the mainstream......»»

Category: topSource: reutersJun 26th, 2019

Before the Move: Watch Sarepta ahead of Pfizer"s DMD gene therapy data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 24th, 2019

Pfizer data next week meaningful for Sarepta, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 21st, 2019

Array BioPharma"s stock soars 56% premarket after Pfizer buyout deal

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchJun 17th, 2019

Baird names Sarepta a "Fresh Pick" ahead of Pfizer data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 9th, 2019

Bulls & Bears Of The Week: Dow, Lyft, Pfizer, Schlumberger, Tesla And More

Benzinga has examined prospects for many investor favorite stocks over the past week. Bullish calls included pharmaceutical and semiconductor leaders. And bearish calls included a fresh IPO and a struggling retailer. read more.....»»

Category: blogSource: benzingaApr 7th, 2019

Pfizer"s DMD Drug Could Spell Long-Term Trouble For Sarepta

Pfizer"s DMD Drug Could Spell Long-Term Trouble For Sarepta.....»»

Category: topSource: seekingalphaApr 16th, 2018

Pfizer"s DMD Drug Could Spell Long Term Trouble For Sarepta

Pfizer"s DMD Drug Could Spell Long Term Trouble For Sarepta.....»»

Category: topSource: seekingalphaApr 16th, 2018

Sarepta"s Stock Soars on Encouraging Gene Therapy Results

Zacks.....»»

Category: topSource: redinewsJun 20th, 2018